Regulus Therapeutics Inc. RGLS
8.16 0.00 (+0.00%)
At closeJun 25, 2025, 4:00 PM EDT
8.16 Day range 8.16
52-week range unavailable
- YTD
- +416.46%
- 1 year
- +298.05%
- Market cap
- 100.22M
- Shares out
- 65.50M
- Forward P/E
- -1.26
- YTD return
- +416.46%
- 1-year return
- +298.05%
- Volume
- 8.76M
- Open
- 8.16
- Previous close
- 8.16
- Day's range
- 8.16 – 8.16
- Beta
- 1.63
- Analysts
- Strong Buy
- Price target
- 10.33 (+26.6%)
2Y +6.73 (+470.63%)
Key statistics
- Enterprise value
- 18.08M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -21.58M
- Total cash
- 87.31M
- Total debt
- 1.24M
- Return on equity
- -72.36%
- Short % of float
- 2.72%
- 50-day average
- 1.53
- 200-day average
- 1.89
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.33 +26.6% upside
Now 8.16
- Target (low)
- 3.00
- Target (mean)
- 10.33
- Target (high)
- 28.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy1
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.23.
Financials — quick view
RGLS Revenue — quarterly 0
RGLS Net income — quarterly -9.63M
RGLS EPS — quarterly -0.15
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.18 | -0.21 | -0.03 | -16.67% |
| Aug 8, 2024 | Jun 1, 2024 | -0.17 | -0.17 | 0.00 | 0.00% |
| May 9, 2024 | Mar 1, 2024 | -0.15 | -0.29 | -0.14 | -93.33% |
| Mar 21, 2024 | Dec 1, 2023 | -0.40 | -0.40 | 0.00 | 0.00% |
| Nov 9, 2023 | Sep 1, 2023 | -0.36 | -0.40 | -0.04 | -11.11% |
| Aug 8, 2023 | Jun 1, 2023 | -0.39 | -0.37 | +0.02 | +5.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Aug 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 25, 2024 | Canaccord Genuity | main | Buy | Buy |
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- regulusrx.com
News
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc.. 
Novartis completes acquisition of Regulus Therapeutics 
Novartis announces commencement of tender offer to acquire Regulus Therapeutics 
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates 
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS 
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS 
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher 
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million 
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders 
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
Your note
Sign in to keep a note on RGLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKER CHRISTOPHER RAY | General Counsel | Sale | Jan 17, 2024 | 10,056 |
| CALSADA CRISPINA CPA | Chief Financial Officer | Sale | Jan 17, 2024 | 5,782 |
| COLLIER KATHRYN J. | Director | Purchase | Jul 24, 2024 | 6,740 |
| HAGAN JOSEPH PATRICK | Chief Executive Officer | Sale | Jan 17, 2024 | 57,112 |
| PAPADOPOULOS STELIOS B | Director | Stock Award(Grant) | Mar 13, 2024 | 978,388 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 19.62% | 12,852,654 | 19.66M | Sep 29, 2024 |
| NEA Management Company, LLC | 9.87% | 6,467,802 | 9.90M | Sep 29, 2024 |
| Vivo Capital, LLC | 7.63% | 5,000,000 | 7.65M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 6.51% | 4,263,701 | 6.52M | Sep 29, 2024 |
| Vanguard Group Inc | 6.24% | 4,088,760 | 6.26M | Sep 29, 2024 |
| Blackrock Inc. | 6.23% | 4,081,038 | 6.24M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 12.03% | 7,881,000 | 12.06M | Jul 30, 2024 |
| Federated Hermes Kaufmann Small Cap Fund | 11.32% | 7,417,000 | 11.35M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 3.82% | 2,501,083 | 3.83M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.47% | 1,617,996 | 2.48M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.73% | 1,130,792 | 1.73M | Sep 29, 2024 |
| USAA Mutual Fund Tr-Science & Technology Fund | 1.43% | 937,813 | 1.43M | Jul 30, 2024 |